

**RISK FACTORS FOR THE MORTALITY OF
TETRALOGY OF FALLOT PATIENTS PERFORMED
TOTAL CORRECTION IN DR.SOETOMO GENERAL
HOSPITAL
THESIS**



Writer:

JULIANA

NIM: 011711133253

INTERNATIONAL CLASS MEDICAL PROGRAM

FACULTY OF MEDICINE

AIRLANGGA UNIVERSITY

SURABAYA

2019

**RISK FACTORS FOR THE MORTALITY OF
TETRALOGY OF FALLOT PATIENTS PERFORMED
TOTAL CORRECTION IN DR.SOETOMO GENERAL
HOSPITAL**

THESIS



Writer:

JULIANA

NIM: 011711133253

INTERNATIONAL CLASS MEDICAL PROGRAM

FACULTY OF MEDICINE

AIRLANGGA UNIVERSITY

SURABAYA

2019

FORM OF APPROVAL

**RISK FACTORS FOR THE MORTALITY OF
TETRALOGY OF FALLOT PATIENTS PERFORMED
TOTAL CORRECTION IN SOETOMO HOSPITAL**

THESIS

**Proposed as One of the Requirements for Completing the Medical Study
Program at the Faculty of Medicine Airlangga University Surabaya**

Oleh:

JULIANA

011711133253

Approved by,

Supervisor I



Dr. H. Mahrus A. Rachman, dr., Sp.A (K)

NIP. 19591213 198802 1 001

Supervisor II



Yan Efrata Sembiring, dr., Sp.B-TKV(K)

NIP. 19750128 200604 1 001

**FACULTY OF MEDICINE
UNIVERSITAS AIRLANGGA
SURABAYA**

2020

EXAMINER'S DECISION SHEET

**RISK FACTORS FOR THE MORTALITY OF
TETRALOGY OF FALLOT PATIENTS PERFORMED
TOTAL CORRECTION IN SOETOMO HOSPITAL**

THESIS

Writer:

JULIANA

011711133253

Approved and accepted after being tested by

Medicine Programme Examiner

Faculty of Medicine Universitas Airlangga Surabaya

Surabaya, 28 Februari 2020

Head of Examiner



Heroe Soebroto, dr., Sp.B., Sp.BTKV(K)
NIP. 19601102 201601 6 101

Supervisor I / Secretary of Examiner



Dr. H. Mahrus A. Rachman, dr., Sp.A (K)

NIP. 19591213 198802 1 001

Supervisor II / Member of Examiner



Yan Efrata Sembiring, dr., Sp.B-TKV(K)

NIP. 19750128 200604 1 001

TABLE OF CONTENTS

OBLIGATION FORM FOR RESEARCH MODUL	ii
FORM OF APPROVAL.....	iii
LIST OF FIGURES	viii
LIST IF ABBREVIATIONS.....	x
1.1 Background.....	1
1.2 Research Question.....	3
1.3 Research Objectives	4
1.3.1 General Objectives	4
1.3.2 Specific Objectives.....	4
1.4 Research Benefits	4
1.4.1 Theoretical Benefits.....	4
1.4.2 Clinical Benefits	4
CHAPTER 2.....	5
2.1 History	5
2.2 Epidemiology	6
2.3 Anatomy	6
2.4 Etiology and Patophysiology	8
2.5 Clinical Manifestation and Diagnosis.....	12
2.6 Management of TOF	15
2.7 Mortality of TOF.....	19

2.8 Risk Factors of TOF	21
2.8.1 Pre-Operative Risk Factors	21
2.8.2 Post-Operative Risk Factors	23
CHAPTER 3	26
3.1 Conceptual Framework	26
3.2 Conceptual Framework Explanation	26
3.3 Early Hypothesis	267
CHAPTER 4	28
4.1 Types and Research Design	28
4.2 Population, Sample and Research Sampling Technique	28
4.2.1 Research Population	28
4.2.2 Research Sample	28
4.2.3 Sample Criteria	28
4.2.4 Sampling Technique	29
4.3 Research Variables and Operational Definitions of Variables	29
4.3.1 Independent Variables	29
4.3.2 Dependent Variables	29
4.3.3. Operational Definitions	29
4.4 Research Instrument	34
4.5 Location and time of Research	34
4.5.1 Research Location	34

4.5.2 Time of Research	34
4.6 Research Procedure for data collection	34
4.7 Processing and Analysis of Data	34
4.8 Research Flow	35
CHAPTER V	35
5.1 Overview of Reseach Sample and Location	35
5.2 Sample Characteristics	35
5.2.1 Distribution of patients based on year, sex and mortality	36
5.2.2 Distribution and Correlation of Patients' Age and Mortality	37
5.2.3 Distribution and Correlation of Patients' Weight and Height to Mortality	38
5.2.4 Distribution and correlation of oxygen saturation, pre-operative hematocrite and mortality	39
5.2.5 Distribution and correlation of History of Hypoxic Spell and Previous BT-Shunt Operation to The Mortality	40
5.2.6 Distribution and correlation of Extra and Intra Cardiac Comorbid Disease and Mortality	41
5.2.7 Distribution and correlation of Post Operative Complication and Mortality	41
5.2.8 Distribution and correlation of ICU Stay, Temperature, Ventilator Time and Mortality	41
CHAPTER VI	44

6.1 Pre-Operative Risk Factors to Mortality	44
6.1.1 Age as The Risk Factor for Mortality	45
6.1.2 Height and Weight as The Risk Factor for Mortality	45
6.1.3 Pre-operative Hematocrit as The Risk Factor for Mortality	46
6.1.4 Hypercyanotic spell as The Risk Factor for Mortality	47
6.1.5 Previous Palliative Treatment as The Risk Factor for Mortality	47
6.1.6 Intra and Extra Comorbid Disease as The Risk Factor for Mortality	48
6.1.7 Pre-operative Oxygen Saturation as The Risk Factor for Mortality .	49
6.2 Post-Operative Risk Factors to Mortality	50
6.2.1 Ventilator duration as The Risk Factor for Mortality	50
6.2.2 ICU Stay as The Risk Factor for Mortality	50
6.2.3 Post-operative Complication as The Risk Factor for Mortality	51
6.2.4 Post-operative fever as The Risk Factor for Mortality	51
6.3 Limitation of This Research	53
CHAPTER VII	53
7.1 Conclusions	53
7.2 Suggestions	54
REFERENCES	35
ATTACHMENT	63

LIST OF FIGURES

Fig 2.1 Anatomical appearance of TOF heart	8
Fig 2.2 The bases of the normal and TOF hearts viewed from the ventricular aspect. The TOF heart shows an intracristal VSD with an overriding aorta, right ventricular hypertrophy, infundibular stenosis and a bicuspid pulmonary valve	9
Fig 2.3 Mechanism of Hypoxic Spell	11
Fig 2.4 Imaging using colour doppler of TOF	14
Fig 2.5 Imaging of TOF	15
Fig 2.6 Chest Radiography of TOF.....	15
Fig 2.7 Schematic Procedure of Total Correction in TOF patients	18
Fig 2.8 Current protocol for timing of repair for neonates and infants with TOF.....	19
Fig 3.1 Conceptual Framework of Research.....	22
Fig 4.1 Flow of this research.....	33

LIST OF TABLES

Table 5.1 Sample characteristics of TOF patient performed total correction.....	36
Tablr 5.2 Distribution of number of patients based on year, sex, and mortality of TOF patient performed total correction.....	37
Table 5.3 Distribution and correlation of patients' age and the mortality.....	38
Table 5.4 Distribution and correlation of weight to mortality.....	38
Table 5.5 Distribution and correlation of patients' age and the mortality.....	39
Table 5.6 Distribution and correlation of oxygen saturation and mortality.....	39
Table 5.7 Distribution and correlation of pre-operative hematocrite and mortality ..	40
Table 5.8 Distribution and correlation of hypoxic spell history and mortality.....	40
Table 5.9 Distribution and correlation of BT-Shunt Operation and mortality	40
Table 5.10 Distribution and correlation of comorbid disease and mortality	41
Table 5.11 Distribution and correlation of postoperative complication and mortality... 41	
Table 5.12 Distribution and correlation of ICU Stay and mortality	42
Table 5.13 Distribution and correlation of Temperature and mortality.....	42
Table 5.14 Distribution and correlation of ventilator time and mortality.....	43

LIST OF ABBREVIATIONS

CHD	: Congenital Heart Disease
CPB	: Cardiopulmonary Bypass
ICU	: Intensive Care Unit
PGE1	: Prostaglandin E1
PS	: Pulmonary Stenosis
RVH	: Right Ventricular Hypertrophy
RVOT	: Right Ventricular Outflow Tract
SVR	: Systemic Vascular Resistant
TOF	: Tetralogy of Fallot
PDA	: Patent Ductus Arteriosus
VIS	: Vasoactive Inotropic Score
VSD	: Ventricular Septal Defect

SURAT PERNYATAAN ORISINILITAS

Yang bertanda tangan dibawah ini, saya:

Nama : Juliana
NIM : 011711133253
Program Studi : Kedokteran
Fakultas : Kedokteran
Jenjang : Sarjana (S1)

Menyatakan bahwa saya tidak melakukan tindakan plagiat dalam penulisan skripsi saya yang berjudul:

RISK FACTORS FOR THE MORTALITY OF TETRALOGY OF FALLOT PATIENTS PERFORMED TOTAL CORRECTION IN SOETOMO HOSPITAL

Apabila suatu saat nanti terbukti melakukan tindakan plagiat, maka saya akan menerima sanksi yang telah ditetapkan.

Demikian surat pernyataan ini saya buat dengan sebenar-benarnya.

Surabaya, 24 Februari 2020



Juliana

ACKNOWLEDGEMENT

I would like to express my greatest gratitude to God Almighty for His unchanging love and gracious blessings so that this thesis entitled **“RISK FACTORS FOR THE MORTALITY OF TETRALOGY OF FALLOT PATIENTS PERFORMED TOTAL CORRECTION IN SOETOMO HOSPITAL”** can be completed and hopefully the findings can be a new gate for future research.

It has been several months of intense learning for me. Writing this research report has had a big impact on me. I would like to express my gratitude on people who have supported and helped me a lot on finishing this report:

1. Dr. H. Mahrus A. Rachman, dr., Sp.A (K) and Yan Efrata Sembiring, dr., Sp.B-TKV(K) supervisors and for their expert advices and also their sincere guidance during the completion of this research.
2. Heroe Soebroto, dr., Sp.B., Sp.BTKV(K) as the thesis examiner for the expert advices and guidance for the completion of this research.
3. Prof. Dr. Mohammad Nasih, SE., Mt., Ak., CMA as the Rector of Universitas Airlangga.
4. Prof. Dr. Soetojo, dr., Sp.U(K) as the Dean of Faculty of Medicine Universitas Airlangga.
5. Prof. Dr. Nancy Margarita Rehatta, dr., Sp.An KIC-KNA as the Coordinator of International Class Faculty of Medicine Airlangga University.
6. Dr. Joni Wahyuhadi, dr., Sp.BS (K) as Director of Dr. Soetomo General Hospital which has given permission to do this research.
7. dr. Tri Wahyu Martanto, Sp.OT (K) as The Head of Research and Development at Dr. Soetomo Hospital which has given permission to perform this research.

8. Atika, S.Si., M.Kes as methodology and statistical supervisor for the guidance and help throughout this research.
9. All lecturers in Faculty of Medicine Universitas Airlangga, who give valuable knowledge and motivation during my study.
10. My most beloved parents, Edison and Melati, for always supporting and praying for me through the difficult time, also my siblings Juliany and July Hartono for their help and support throughout the process of completing this thesis.
11. My special friend, Putu Jaya Kusuma, for the motivation and support and also for the help on completing this thesis.
12. All my frenemies in Rokitansky-Gianuzzi : Diska Hanifah, Assyadilla Kirana, Nadira Muthi, Erlangga Lazuardi, Gading Yudha, Andi Muh Rahul, Alfisar Shidqi for the 'fun quizzes' and support that really help me on surviving in FK.
13. My angelic friends : Almira Maharani, Priyadashini AP Surendra, Nadine Amadea Intan for staying together and helping me on surviving in class.
14. My long distance emotional support; Iter Nostrum (Azzahra Asyisyifa, M.Rizqi Amir, Farras M. Razan, M. Falah Nur I), for their endless prayer and support, I am so lucky to have you guys.
15. To "teman gap sebelah" : Junjungan N, Gading Yudha, Danise Febiola, Feriawan Tan, Januar Rizqi, and the rest of smala people who has filled my day with lots of jokes, preventing me feeling burn out, thankyou.
16. To Dr. Luqman Alwi for the help and guidance on making proposal until the process of finding data so that this research can be completed.
17. My senior, Kak Adnya and Kak Ovin for sharing their knowledge and helping me on finishing this thesis.

18. To Smala girls + (some of) Mojo boys : Dini I.B, Annisya Dinda, Arisvia S, Dian Awalia, Tijani Z, Saskia R.D, Yogi Prema, Rizki Dimasyah, Pamarga for their birthday treat every year so I am fully energized and healthy so I can complete this research, I am beyond grateful.

19. Last but not least, all of my valuable friends in Astrocytes 2017 who has surviving and completing thesis together and for supporting each other until we finish our study in FK, we are almost there gais.

Hopefully, the result of this research can be beneficial to many people. Advices and criticism from the readers are expected for the perfection of this research report.

Surabaya, 28th February 2020

Juliana